Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007563 | 0.80 | LOXL2 (0.41) | KIF11LOXL2LMNAALDH1A1CYP2D6 | |
| SCHEMBL17403432 | 0.80 | KIF11 (0.40) | KIF11LOXL2LMNAALDH1A1CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL28726489 | 0.78 | KIF11 (0.39) | KIF11LOXL2LMNAALDH1A1CYP2D6 | |
| SCHEMBL27563226 | 0.77 | TAAR1 (0.48) | ALDH1A1CYP2D6MAPTCYP1A2CYP3A4 | |
| SCHEMBL15065574 | 0.76 | CYP19A1 (0.51) | KIF11LMNACYP1A2CYP3A4CYP19A1 | |
| SCHEMBL1515567 | 0.74 | KIF11 (0.46) | KIF11LOXL2LMNAALDH1A1CYP2D6 | |
| SCHEMBL6672912 | 0.72 | KIF11 (0.49) | KIF11ALDH1A1CYP2D6CYP1A2CYP3A4 | |
| SCHEMBL17047180 | 0.72 | CYP2C19 (0.44) | KIF11LMNAALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL28773136 | 0.72 | CYP2C19 (0.44) | KIF11LMNAALDH1A1CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL1919525 | 0.72 | KIF11 (0.44) | KIF11LOXL2LMNAALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111182898-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| CN-104244944-A | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS INC | 2014-12-24 | — | — | CN | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2809322-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| CN-104203239-A | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS INC | 2014-12-10 | — | — | CN | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013142236-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | KIF11 914/4885LOXL2 3456/4885LMNA 235/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | KIF11 3740/4885LOXL2 2548/4885LMNA 1303/4885 |
| US-11702646-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, HNRNPM | KIF11 3740/4885LOXL2 2548/4885LMNA 1303/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | KIF11 3496/4885LOXL2 2225/4885LMNA 1199/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | KIF11 3496/4885LOXL2 2225/4885LMNA 1199/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | KIF11 943/4885LOXL2 4019/4885LMNA 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.